Celldex Therapeutics Inc. (CLDX) Trading Down 1.8%
Celldex Therapeutics Inc. (NASDAQ:CLDX) shares dropped 1.8% during mid-day trading on Tuesday . The company traded as low as $3.83 and last traded at $3.83, with a volume of 1,779,469 shares changing hands. The stock had previously closed at $3.90.
CLDX has been the topic of a number of research analyst reports. Jefferies Group restated a “hold” rating and set a $4.00 price target on shares of Celldex Therapeutics in a report on Friday, May 6th. Wedbush reiterated a “neutral” rating and set a $3.00 target price on shares of Celldex Therapeutics in a report on Friday, May 6th. Finally, Cowen and Company reiterated an “outperform” rating and set a $12.00 target price on shares of Celldex Therapeutics in a report on Tuesday, June 7th. Six analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Celldex Therapeutics presently has an average rating of “Hold” and an average target price of $10.75.
The company has a 50 day moving average price of $4.52 and a 200 day moving average price of $4.63. The company’s market cap is $380.06 million.
Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.32) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.34) by $0.02. During the same period in the previous year, the business posted ($0.33) EPS. The business earned $1.39 million during the quarter, compared to the consensus estimate of $0.96 million. The firm’s revenue was down 36.4% on a year-over-year basis. Equities analysts predict that Celldex Therapeutics Inc. will post ($1.34) earnings per share for the current year.
Celldex Therapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.